Trending
- Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
- When Single-Fraction SRS Still Makes Sense for Resected Brain Metastases
- Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma
- BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
- Genetics and treatment history influence clonal hematopoiesis risk after PARP inhibitor therapy
- SRS Improves Survival Vs Hippocampal Avoidant-WBRT in SCLC Brain Metastases
- Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape
- Extended Belantamab Mafodotin Dosing Eases Ocular Function in DREAMM-9
Wednesday, September 30